Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Venkata Nagineni"'
Autor:
Roy S Herbst, Vamsidhar Velcheti, Mari Mino-Kenudson, Matthew D Hellmann, David L Rimm, Kurt A Schalper, Anant Madabhushi, Justin Gainor, Germán Corredor, Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Cristian Barrera, Lindsey Behlman, Jonathan W Riess
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/dd6140760c244b16852a5797f0cd5927
Autor:
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera, Lindsey Behlman, David L Rimm, Roy S Herbst, Anant Madabhushi, Jonathan W Riess, Vamsidhar Velcheti, Matthew D Hellmann, Justin Gainor, Kurt A Schalper
Publikováno v:
Journal for immunotherapy of cancer. 10(6)
BackgroundTumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b810738bfb286d6138477a8fcd4edfe5
https://pubmed.ncbi.nlm.nih.gov/35649657
https://pubmed.ncbi.nlm.nih.gov/35649657
Autor:
Ming Zhou, Ye Feng, Qiuyan Wu, Venkata Nagineni, Hongyu Zhao, Jose Luis Perez-Gracia, Jianlei Gu, Miguel F. Sanmamed, Shu-Pang Huang, Darren Locke, Vipul Baxi, Nicole Gianino, Timothy Baradet, Kurt A. Schalper, Penny Phillips, Tian Chen, Alice M. Walsh, Michael Carleton, Timothy P. Reilly, Ignacio Melero, Dimple Pandya
Publikováno v:
Nat Med
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d331d2a10b6b18cdcddc65e357fd5d9
https://doi.org/10.1038/s41591-020-0856-x
https://doi.org/10.1038/s41591-020-0856-x
Autor:
Miguel Lopez de Rodas Gregorio, Venkata Nagineni, Arvind Ravi, Ila J. Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera, Lindsey Behlman, David L. Rimm, Roy S. Herbst, Anant Madabhushi, Jonathan W. Riess, Vamsidhar Velcheti, Matthew Hellmann, Justin F. Gainor, Kurt A. Schalper
Publikováno v:
Cancer Research. 82:1722-1722
The rapid clinical expansion of immune checkpoint blockers (ICB) has transformed the therapeutic arsenal for non-small cell lung cancer (NSCLC). However, only a relatively small fraction of patients benefits from these treatments and those who respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0166dc95eb357fec4b5837625b2cd7fa
https://doi.org/10.1158/1538-7445.am2022-1722
https://doi.org/10.1158/1538-7445.am2022-1722